TY - JOUR
T1 - Comparative performances of HIV-1 RNA load assays at low viral load levels
T2 - Results of an international collaboration
AU - Swenson, Luke C.
AU - Cobb, Bryan
AU - Geretti, Anna Maria
AU - Harrigan, P. Richard
AU - Poljak, Mario
AU - Seguin-Devaux, Carole
AU - Verhofstede, Chris
AU - Wirden, Marc
AU - Amendola, Alessandra
AU - Boni, Jurg
AU - Bourlet, Thomas
AU - Huder, Jon B.
AU - Karasi, Jean Claude
AU - Lepej, Snjezana Zidovec
AU - Lunar, Maja M.
AU - Mukabayire, Odette
AU - Schuurman, Rob
AU - Tomažič, Janez
AU - Van Laethem, Kristel
AU - Vandekerckhove, Linos
AU - Wensing, Annemarie M.J.
PY - 2014/2
Y1 - 2014/2
N2 - Low-level viremia during antiretroviral therapy and its accurate measurement are increasingly relevant. Here, we present an international collaboration of 4,221 paired blood plasma viral load (pVL) results from four commercial assays, emphasizing the data with low pVL. The assays compared were the Abbott RealTime assay, the Roche Amplicor assay, and the Roche TaqMan version 1 and version 2 assays. The correlation between the assays was 0.90 to 0.97. However, at a low pVL, the correlation fell to 0.45 to 0.85. The observed interassay concordance was higher when detectability was defined as 200 copies/ml than when it was defined as 50 copies/ml. A pVL of ∼ 100 to 125 copies/ml by the TaqMan version 1 and version 2 assays corresponded best to a 50-copies/ml threshold with the Amplicor assay. Correlation and concordance between the viral load assays were lower at a low pVL. Clear guidelines are needed on the clinical significance of low-level viremia.
AB - Low-level viremia during antiretroviral therapy and its accurate measurement are increasingly relevant. Here, we present an international collaboration of 4,221 paired blood plasma viral load (pVL) results from four commercial assays, emphasizing the data with low pVL. The assays compared were the Abbott RealTime assay, the Roche Amplicor assay, and the Roche TaqMan version 1 and version 2 assays. The correlation between the assays was 0.90 to 0.97. However, at a low pVL, the correlation fell to 0.45 to 0.85. The observed interassay concordance was higher when detectability was defined as 200 copies/ml than when it was defined as 50 copies/ml. A pVL of ∼ 100 to 125 copies/ml by the TaqMan version 1 and version 2 assays corresponded best to a 50-copies/ml threshold with the Amplicor assay. Correlation and concordance between the viral load assays were lower at a low pVL. Clear guidelines are needed on the clinical significance of low-level viremia.
UR - http://www.scopus.com/inward/record.url?scp=84893124451&partnerID=8YFLogxK
U2 - 10.1128/JCM.02461-13
DO - 10.1128/JCM.02461-13
M3 - Article
C2 - 24478482
AN - SCOPUS:84893124451
SN - 0095-1137
VL - 52
SP - 517
EP - 523
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
IS - 2
ER -